senolytic peptide foxo4-dri human study Development of a novel by precise disruption of FOXO4-p53 complex FOXO4-DRI: Human Trial Status, Cancer

The human equivalent dose of approximately 0.035 mg is extremely small, suggesting that even standard anti-aging doses could provide some degree of neurological benefit as a secondary effect

N.FlemetakisE.PapageorgiouA

The practical implication is that GHK-Cu addresses structural skin aging (collagen loss, elasticity decline) while neurotransmitter-modulating peptides address dynamic wrinkles (expression lines)

This product is not intended to diagnose, treat, cure, mitigate, or prevent any disease and is not intended for ingestion by humans or animals.

Evaluation of heterotopic bone formation induced by squalane and bone morphogenetic protein composite